Of Price And Premiums: Medicare Has Put Alzheimer’s Drug Sponsors On Notice
Executive Summary
Medicare will be closely watching for pricing decisions by Eli Lilly, Eisai and Roche once the companies gain US marketing approval for their amyloid-directed monoclonal antibody drugs for Alzheimer’s disease.
You may also be interested in...
Medicaid Adoption Of Medicare CED Restrictions For Alzheimer’s Drugs Weighed By MACPAC
Medicaid advisory panel members suggest states should have the same flexibility as Medicare to adopt coverage with evidence development requirements for drugs with limited supporting evidence.
Medicare Part B Premium Reduction In 2023 Has Reserves Built In If Lecanemab Launches
But premiums in future years made need to keep pace with accelerating Medicare spending on Alzheimer’s drugs.
Lilly Phase III Alzheimer’s Data Will Set Stage For Unrestricted Medicare Coverage Request
Donanemab results due next year have a good chance of persuading CMS to offer unrestricted coverage, Lilly argues, even though the drug might just have accelerated approval at that point. ‘We believe that having two positive pivotal trials should meet that high level of evidence.’